Instrument NameNovo Nordisk A/S ADRInstrument Symbol(NVO-N)

Instrument ExchangeNYSE

With volatility on the increase, option premiums are elevated which could mean it’s a great time for iron condor trades.

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its next blockbuster drug, CagriSema.

Many investors have a type of acrophobia (the fear of heights). It's not that they're worried about standing at the top of a ladder. Instead, their concern is focused on putting money in stocks when the market is skyrocketing.

Mergers and acquisitions could make a comeback with Trump headed back to Washington.

Hims & Hers, Payoneer, and Astera Labs lead Q3 earnings with standout revenue growth, forecast upgrades, and strategic wins—stocks to watch for growth potential

The good times aren't over, but the peak of the party might be passing.

Viking stock has slipped more than 20% from its peak.

We're also talking about Super Micro, Nvidia, and weight loss.

Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.

NVO earnings call for the period ending September 30, 2024.

Size means little in light of this company's prospects.

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly.

Monday U.S. Economic Lookahead Factory orders (Sept.) Featured Earnings Vertex Pharmaceuticals ...

Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors

Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth.

One key disease-prevention market is drawing closer to being within reach.

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.

Stan Wong of Scotia Wealth Management is an active money manager who invests based on macroeconomic, quantitative and technical analysis

After more than doubling in the past year, is this clinical-stage biotech stock still a buy?

The GLP-1 drama continues at Hims & Hers.

/CNW/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it's...

Energy drinks face negative publicity and competition, leading to sell-offs in Monster and Celsius. Increasing foot traffic may offer hope for a recovery.

One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.

Paul Harris of Harris Douglas Asset Management says he hasn’t sold a stock since 2020. ‘I don’t feel the need to sell anything’